Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural kille...
Q1 2026
May 12, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 12, 2025
